

Liise-anne Pirofski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6017140/publications.pdf>

Version: 2024-02-01

46
papers

2,705
citations

236925

25
h-index

315739

38
g-index

56
all docs

56
docs citations

56
times ranked

5790
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	5.9	38
2	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine, 2022, 182, 115.	5.1	63
3	WHO covid-19 drugs guideline: reconsider using convalescent plasma. BMJ, The, 2022, 376, o295.	6.0	6
4	<i>mBio</i> Welcomes Clinical Research Papers That Advance Our Understanding of Human-Microbe Interactions. MBio, 2022, , e0052722.	4.1	0
5	Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. JCI Insight, 2021, 6, .	5.0	36
6	Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. MSphere, 2021, 6, .	2.9	11
7	Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseasesâ€“Critical Care Medicine Service in Critical Care Units. Open Forum Infectious Diseases, 2021, 8, ofab182.	0.9	0
8	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. MBio, 2021, 12, .	4.1	62
9	SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. Journal of Clinical Investigation, 2021, 131, .	8.2	47
10	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2021, 96, 1262-1275.	3.0	129
11	Use of convalescent plasma in<scp>COVID</scp>â€“19 patients with immunosuppression. Transfusion, 2021, 61, 2503-2511.	1.6	70
12	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	2.6	50
13	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 2021, 13, 1594.	3.3	31
14	Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. New England Journal of Medicine, 2021, 384, 189-189.	27.0	12
15	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega, 2021, 6, 85-102.	3.5	54
16	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Nature Communications, 2021, 12, 6853.	12.8	41
17	Extracellular Vesicles from Different Pneumococcal Serotypes Are Internalized by Macrophages and Induce Host Immune Responses. Pathogens, 2021, 10, 1530.	2.8	7
18	The Assessment of Convalescent Plasma Efficacy against COVID-19. Med, 2020, 1, 66-77.	4.4	17

#	ARTICLE	IF	CITATIONS
19	Human IgM Inhibits the Formation of Titan-Like Cells in <i>Cryptococcus neoformans</i> . <i>Infection and Immunity</i> , 2020, 88, .	2.2	16
20	A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 455.	7.4	90
21	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. <i>Cell Host and Microbe</i> , 2020, 28, 486-496.e6.	11.0	178
22	Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. <i>MBio</i> , 2020, 11, .	4.1	54
23	The convalescent sera option for containing COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 1545-1548.	8.2	775
24	Early Infectious Disease Consultation Is Associated With Lower Mortality in Patients With Severe Sepsis or Septic Shock Who Complete the 3-Hour Sepsis Treatment Bundle. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz408.	0.9	25
25	Benefits and Costs of Animal Virulence for Microbes. <i>MBio</i> , 2019, 10, .	4.1	27
26	Antibody Immunity and Natural Resistance to <i>Cryptococcosis</i> . <i>Current Tropical Medicine Reports</i> , 2019, 6, 50-54.	3.7	3
27	Is Burnout Infectious? Understanding Drivers of Burnout and Job Satisfaction Among Academic Infectious Diseases Physicians. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz092.	0.9	14
28	A semisynthetic <i>Streptococcus pneumoniae</i> serotype 8 glycoconjugate vaccine. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	73
29	Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline. <i>Journal of Infectious Diseases</i> , 2017, 216, S611-S612.	4.0	4
30	Developing Interactive Antimicrobial Stewardship and Infection Prevention Curricula for Diverse Learners: A Tailored Approach. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx117.	0.9	27
31	Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination. <i>Vaccine Journal</i> , 2016, 23, 524-529.	3.1	0
32	A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against <i>Streptococcus pneumoniae</i> Serotype 3 Infection. <i>Cell Chemical Biology</i> , 2016, 23, 1407-1416.	5.2	51
33	Reduction of <i>Streptococcus pneumoniae</i> Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody. <i>MBio</i> , 2016, 7, e02260-15.	4.1	19
34	What Is a Host? Incorporating the Microbiota into the Damage-Response Framework. <i>Infection and Immunity</i> , 2015, 83, 2-7.	2.2	89
35	The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases. <i>PLoS Pathogens</i> , 2015, 11, e1004717.	4.7	30
36	An Ahemolytic Pneumolysin of <i>Streptococcus Pneumoniae</i> Manipulates Human Innate and CD4 ⁺ T-Cell Responses and Reduces Resistance to Colonization in Mice in a Serotype-Independent Manner. <i>Journal of Infectious Diseases</i> , 2014, 210, 1658-1669.	4.0	14

#	ARTICLE	IF	CITATIONS
37	Characterization of protective extracellular membrane-derived vesicles produced by <i>Streptococcus pneumoniae</i> . <i>Journal of Proteomics</i> , 2014, 106, 46-60.	2.4	203
38	Microbiology: Ditch the term pathogen. <i>Nature</i> , 2014, 516, 165-166.	27.8	99
39	Report from the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Joint Conference 2008: Washington, DC, USA, October 25-28, 2008. <i>Journal of Invasive Fungal Infections</i> , 2009, 2, 151-154.	0.0	0
40	The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2008, 635, 135-146.	1.6	81
41	Of Mice and Men, Revisited: New Insights into an Ancient Molecule from Studies of Complement Activation by <i>Cryptococcus neoformans</i> . <i>Infection and Immunity</i> , 2006, 74, 3079-3084.	2.2	12
42	A Human IgM Monoclonal Antibody Prolongs Survival of Mice with Lethal <i>Cryptococcosis</i> . <i>Journal of Infectious Diseases</i> , 1998, 178, 1213-1216.	4.0	78
43	Acquired Antibody-Mediated Immunity to Fungi. , 0, , 487-503.		1
44	Vaccines and Antibody Therapies from <i>Cryptococcus neoformans</i> to Melanoma. , 0, , 537-546.		1
45	Acquired Humoral Immunity to <i>Cryptococcus neoformans</i> . , 0, , 397-408.		0
46	<i>Cryptococcus neoformans</i> -specific and non- <i>Cryptococcus neoformans</i> -specific antibody profiles in organ transplant recipients with and without <i>cryptococcosis</i> . <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	2